Insights

More Articles Back to Article

Aslan's acute myeloid leukemia candidate shows potential

Pre-clinical data published in the Haematologica Journal showed Aslan Pharmaceuticals' experimental candidate ASLAN003 as having potential to treat acute myeloid leukemia. The company is studying future development plans for the drug after the completion of a Phase IIa trial for ASLAN003. Seeking Alpha (11/22)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!